LXEO – lexeo therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics
Lexeo Therapeutics (NASDAQ:LXEO) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $17.00 price target on the stock.
Lexeo Therapeutics (NASDAQ:LXEO) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy [Yahoo! Finance]
Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy
Form SCHEDULE 13G Lexeo Therapeutics, Inc. Filed by: VANGUARD GROUP INC
Form SCHEDULE 13G/A Lexeo Therapeutics, Inc. Filed by: Affinity Asset Advisors, LLC
Form 8-K Lexeo Therapeutics, Inc. For: Jan 27
Form SCHEDULE 13G Lexeo Therapeutics, Inc. Filed by: BlackRock, Inc.
Form 8-K Lexeo Therapeutics, Inc. For: Jan 12
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.